sarcosine has been researched along with imatinib mesylate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, J; Craige, CP; Lauretti, E; Praticò, D | 1 |
| Huang, HM; Lee, YL; Liu, FH; Wong, SM | 1 |
2 other study(ies) available for sarcosine and imatinib mesylate
| Article | Year |
|---|---|
Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Benzamides; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; Humans; Imatinib Mesylate; Mice; Mice, Transgenic; Mutation; Neuroblastoma; Peptide Fragments; Phosphorylation; Piperazines; Plaque, Amyloid; Presenilin-1; Proteins; Pyrimidines; Sarcosine; Statistics, Nonparametric; tau Proteins | 2014 |
MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Sarcosine; Signal Transduction; Sulfonamides; Tubulin Modulators | 2016 |